Ei­sai prices Alzheimer's drug at $26,500, be­low part­ner Bio­gen's Aduhelm

Ei­sai and Bio­gen will price their new Alzheimer’s treat­ment Leqem­bi at $26,500 per year, US CEO Ivan Che­ung tells End­points News. With out­cries over the pric­ing of the drug­mak­ers’ pre­vi­ous drug, Aduhelm, all eyes are on the stick­er price for the duo’s new treat­ment cleared by the FDA on Fri­day.

Leqem­bi will like­ly be in­fused in few pa­tients at this stage, as the US gov­ern­ment’s in­sur­er for those over the age of 65 puts a lim­it on cov­er­age of an­ti-amy­loid drugs fol­low­ing the Aduhelm nod. Pa­tients es­sen­tial­ly have to be in a clin­i­cal tri­al to get cov­er­age from the Cen­ters for Medicare & Med­ic­aid Ser­vices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.